C Blome1, M Augustin, D Siepmann, N Q Phan, S J Rustenbach, S Ständer. 1. CVderm-German Center for Health Services Research in Dermatology, Research Group Health Economics and Quality of Life Research, Department of Dermatology and Venereology, University Clinics of Hamburg, D-20246 Hamburg, Germany.
Abstract
BACKGROUND: The assessment of patient-relevant benefit is gaining importance in evaluating treatments. The 'Patient Benefit Index, standard version' questionnaire (PBI-S) is a validated instrument to assess patients' treatment needs and benefits in skin diseases. Before therapy, the patient rates the importance of predefined treatment goals; after therapy, he rates the extent to which these goals have been achieved. Thus far, no such instrument has been developed specifically for pruritus. OBJECTIVES: Development and validation of a patient-relevant benefit questionnaire in the treatment of pruritus. METHODS: Fifty patients with pruritus were questioned on impairments due to pruritus and treatment needs. Four treatment objectives not already covered by the PBI-S were added to obtain a disease-specific instrument. This was tested for feasibility by 36 patients with pruritus and validated in a sample of 100 patients with pruritus. RESULTS: The instrument was feasible in clinical practice. There were < 2% missing values. Cronbach's alpha of the needs questionnaire was 0.93. Convergent validity was demonstrated with respect to reduction of pruritus and quality of life. CONCLUSIONS: The PBI for pruritus is a feasible, reliable and valid instrument that is highly accepted in daily routine for recording patient-reported benefit.
BACKGROUND: The assessment of patient-relevant benefit is gaining importance in evaluating treatments. The 'Patient Benefit Index, standard version' questionnaire (PBI-S) is a validated instrument to assess patients' treatment needs and benefits in skin diseases. Before therapy, the patient rates the importance of predefined treatment goals; after therapy, he rates the extent to which these goals have been achieved. Thus far, no such instrument has been developed specifically for pruritus. OBJECTIVES: Development and validation of a patient-relevant benefit questionnaire in the treatment of pruritus. METHODS: Fifty patients with pruritus were questioned on impairments due to pruritus and treatment needs. Four treatment objectives not already covered by the PBI-S were added to obtain a disease-specific instrument. This was tested for feasibility by 36 patients with pruritus and validated in a sample of 100 patients with pruritus. RESULTS: The instrument was feasible in clinical practice. There were < 2% missing values. Cronbach's alpha of the needs questionnaire was 0.93. Convergent validity was demonstrated with respect to reduction of pruritus and quality of life. CONCLUSIONS: The PBI for pruritus is a feasible, reliable and valid instrument that is highly accepted in daily routine for recording patient-reported benefit.
Authors: S Ständer; C Blome; B Breil; P Bruland; U Darsow; M Dugas; A Evers; F Fritz; M Metz; N Q Phan; U Raap; A Reich; G Schneider; S Steinke; J Szepietowski; E Weisshaar; M Augustin Journal: Hautarzt Date: 2012-07 Impact factor: 0.751
Authors: C Blome; A Costanzo; E Dauden; C Ferrandiz; G Girolomoni; R Gniadecki; L Iversen; A Menter; K Michaelis-Wittern; A Morita; H Nakagawa; K Reich; M Augustin Journal: Qual Life Res Date: 2015-10-03 Impact factor: 4.147
Authors: Manuel P Pereira; Claudia Zeidler; Michael Storck; Konstantin Agelopoulos; Wolfgang G Philipp-Dormston; Alexander Zink; Sonja Ständer Journal: Acta Derm Venereol Date: 2020-01-07 Impact factor: 3.875